Navigation Links
NutraCea Announces First Quarter 2008 Financial Results
Date:5/12/2008

NUTRACEA AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS

March 31, December 31,

2008 2007

(Unaudited)

ASSETS

Current assets:

Cash and cash equivalents $5,816,000 $41,298,000

Restricted cash 5,281,000 758,000

Trade accounts receivable,

net of allowance for doubtful

accounts of $3,168,000 and

$2,999,000, respectively 3,066,000 2,346,000

Inventories 3,831,000 1,808,000

Notes receivable, current portion,

net of allowance for doubtful notes

receivable of $543,000 and $250,000,

respectively 7,145,000 2,936,000

Deposits and other current assets 2,480,000 2,545,000

Total current assets 27,619,000 51,691,000

Restricted cash 1,791,000 1,791,000

Notes receivable, net of current portion 44,000 5,039,000

Property and equipment, net 38,939,000 19,328,000

Investment in joint venture 9,348,000 1,191,000

Patents and trademarks, net of

accumulated amortization 5,534,000 5,743,000

Other non-current 50,000 -

Goodwill 52,765,000 39,510,000

Total assets $136,090,000 $124,293,000

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities $13,646,000 $7,506,000

De
'/>"/>

SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. NutraCea Appoints Financial Relations Board as New Investor Relations Firm
2. NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14
3. NutraCea Announces Conference Call to Report Second Quarter Financial Results
4. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
5. NutraCea Provides Update on Domestic Operations
6. NutraCea Files Universal Shelf Registration Statement
7. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
8. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
9. NutraCea Appoints New Chief Financial Officer
10. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
11. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...rise in England, accounting for more than 1 millio...epartment each year. The findings are based on an...mergency department of a hospital in South West En...cy care was also asked to assess the need for trea...
...rchers has found that kidney disease may be a more...esterol. Studies conducted on mice have revealed t... adiponectin may also have high levels of a protei...n kidney disease. A negative correlation was foun...
...eld scope called VELscope, which has been develope...ional Institute of Dental Craniofacial Research. T...n the conventional white light in detection of can...e very useful for early detection of oral cancer a...
...n jailed for life for bludgeoning his friend Stuar...sgow's Pollok Park. He attacked his friend less t...ric hospital where a judge had ordered he be detai...r violent assault. Stuart Robertson, a father of ...
Other Medicine News:Health News:Man Bludgeons Friend, Gets Life Term 2
(Date:7/23/2008)...- Sound Pharmaceuticals (SPI) has filed,an Investi... clinical,testing of a proprietary formulation of ... hearing loss or ototoxicity. The oral capsule,con...ced stage lung cancer,and head and neck cancer pat...marks the second development program for SPI to en...
(Date:7/23/2008)... FluoroPharma Inc., a company developing,breakthro...sion Tomography,(PET) market, announced positive P...beled tracer for myocardial perfusion imaging. BFP... to complete Phase I clinical,development., BFPET...ood flow in the,heart (myocardial perfusion). Myoc...
(Date:7/23/2008)...ire/ -- InCode BioPharmaceutics, Inc.,an emerging...nical test,results demonstrating the utility of th... the rare chronic blood disorder paroxysmal noctur...l be presented at the XXII,International Complemen...08., The only treatment currently available for P...
(Date:7/23/2008)... Work with Protein Therapeutics that Mod...AMBRIDGE, Mass., July 23 /- Taligen T...a corporate growth plan with the,appointment of Ab...d the,establishment of its headquarters in Cambrid...D., a co-founder of the company who remains presid...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 1Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 2Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 4AAHC Examines Nations Clinical Trials Infrastructure 620 1AAHC Examines Nations Clinical Trials Infrastructure 620 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 1Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 3Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 4Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 1Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 2Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 3Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 4Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 5Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 6Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 7Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 8Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 9Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 10Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 11Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 12
...THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007...ced final results of a U.S.,Phase 2 study of Proel...ymptoms of uterine fibroids. This study suggests t...ally highly,significant improvement in symptoms as...ll tolerated., Study Details and Results , This 12...
...PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - A...nced the publication by its,majority-owned subsidi...strating the anti-proliferative effect of the siRN...f its lead anti-cancer,compound, CALAA-01., The pa...eotide,Reductase Subunit RRM2 Reduce Cell Prolifer...
Other Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: